Efficacy of replication-defective adenovirus-vectored vaccines: Protection following intramuscular injection is linked to promoter efficiency in muscle representative cells

Virology

Volumn 238, Issue 2, 1997, Pages 327-335

  Ambriović, Andreja ^a   Adam, Micheline ^a   Monteil, Martine ^a   Paulin, Denise ^b   Eloit, Marc ^a  

^a ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

DNA immunization; Promoter; Pseudorabies virus glycoprotein D; Recombinant adenovirus; Vaccine

Indexed keywords

CYTOKINE; DESMIN; PLASMID DNA; VIRUS GLYCOPROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; EMBRYO; ENHANCER REGION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMEDIATE EARLY GENE; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; LONG TERMINAL REPEAT; MOUSE; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PSEUDORABIES HERPETOVIRUS; ROUS SARCOMA ONCOVIRUS; VIRUS REPLICATION;

EID: 0031585537     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8842     Document Type: Article

References (62)

1. Acsadi G., Jani A., Huard J., Blaschuk K., Massie B., Holland P., Lochmuller H., Karpati G. Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants. Gene Ther. 1:1994;338-340.
2. Adam M., Lepottier M. F., Eloit M. Vaccination of pigs with replication-defective adenovirus vectored vaccines: The example of pseudorabies. Vet. Microbiol. 42:1994;205-215.
3. Ali M., Lemoine N. R., Ring C. J. A. The use of DNA viruses as vectors for gene therapy. Gene Ther. 1:1994;367-384.
4. Babiss L. E., Friedman J. M., Darnell J. E. Cellular promoters incorporated into the adenovirus genome: Effects of viral regulatory elements on transcription rates and cell specificity of albumin and β-globin promoters. Mol. Cell Biol. 6:1986;3798-3806.
5. Ballay A., Levrero M., Tiollais P., Perricaudet M. Hepdnaviruses-U.C.L.A. Symposia on molecular and Cellular Biology. New Series. 70:1987;Alan R. Liss, New York. p. 481-493.
6. Berman P., Dowbenko D., Lasky L. A. Detection of antibodies to herpes simplex virus with a continuous cell line expressing cloned glycoprotein D. Science. 222:1983;524-527.
7. Both G. W., Lockett L. J., Janardhana V., Edwards S. J., Bellamy A. R., Graham F. L., Prevec L., Andrew M. E. Protective immunity to rotavirus-induced diarrhoea is passively transfered to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc. Virology. 193:1993;940-950.
8. Boshart M., Weber F., Jahn G., Dorsch-Hasler K., Fleckenstein B., Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell. 41:1985;521-530.
9. Brockmeier S. L., Lager K. M., Tartaglia J., Riviere M., Paoletti E., Mengeling W. L. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses. Vet. Microbiol. 38:1993;41-58.
10. Caravokyri C., Pringle C. R., Leppard K. N. Human adenovirus type-5 recombinants expressing simian immunodeficiency virus macaque strain gag antigens. J. Gen. Virol. 74:1993;2819-2824.
11. Corr M., Lee D. J., Carson D. A., Tighe H. Gene vaccination with naked plasmid DNA: Mechanism of CTL priming. J. Exp. Med. 184:1996;1555-1560.
12. Cox G. J. M., Zamb T. J., Babiuk L. A. Bovine herpesvirus 1: Immune responses in mice and cattle injected with plasmid DNA. J. Virol. 67:1993;5664-5667.
13. Cremer K. J., Mackett M., Wohlenberg C., Notkins A. L., Moss B. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science. 228:1985;737-740.
14. Coney L., Wang B., Ugen K. E., Boyer J., McCallus D., Srikantan V., Agadjanyan M., Pachuk C. J., Herold K., Merva M., Gilbert L., Deng K., Moelling K., Newman M., Williams V. W., Weiner D. B. Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo. Vaccine. 12:1994;1545-1550.
15. Davis H. L., Michel M.-L., Mancini M., Schleef M., Whalen R. G. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B surface antigen. Vaccine. 12:1994;1503-1509.
16. Davis H. L., Demeneix B. A., Quantin B., Coulombe J., Whalen R. G. Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum. Gene Ther. 4:1993;733-740.
17. Eloit M., Adam M. Isogenic adenoviruses type 5 expressing or not expressing the E1A gene: Efficiency as virus vectors in the vaccination of permissive and non-permissive species. J. Gen. Virol. 76:1995;1583-1589.
18. Eloit M., Bouzghaia H., Toma B. Identification of antigen sites on pseudorabies virus glycoprotein gp50 implicated in virus penetration of the host cell. J. Gen. Virol. 71:1990a;2179-2183.
19. Eloit M., Fargeaud D., L'Haridon R., Toma B. Identification of the pseudorabies virus glycoprotein gp50 as a major target of neutralizing antibodies. Arch. Virol. 99:1988;45-56.
20. Eloit M., Gilardi-Hebenstreit P., Toma B., Perricaudet M. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. J. Gen. Virol. 71:1990b;2425-2431.
21. Ertl H. C. J., Verma P., He Z., Xiang Z. Q. Plasmid vectors as anti-viral vaccines. Ann. N.Y. Acad. Sci. 772:1995;77-87.
22. Fynan E. F., Webster R. G., Fuller D. H., Haynes J. R., Santoro J. C., Robinson H. L. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA. 90:1993;11478-11482.
23. Ganne V., Eloit M., Laval A., Adam M., Trouve G. Enhancement of the efficacy of a replication-defective adenovirus-vectored vaccine by the addition of oil adjuvants. Vaccine. 12:1994;1190-1196.
24. Gerard R. D., Meidell R. S. Adenovirus-mediated gene transfer. Trends Cardiovasc. Med. 3:1993;171-177.
25. Ghiasi H., Cai S., Slanina S., Nesburn A. B., Wechsler S. L. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. Antiviral Res. 28:1995;147-157.
26. Ghiasi H., Kaiwar R., Nesburn A. B., Slanina S., Wechsler S. L. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH and gI): Comparative protection against lethal challenge in mice. J. Virol. 68:1994;2118-2126.
27. Goebels N., Michaelis D., Wekerle H., Hohlfeld R. Human myoblasts as antigen-presenting cells. J. Immunol. 149:1992;661-667.
28. Gorman C. M., Merlino G. T., Willingham M. C., Pastan I., Howard B. H. The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eucaryotic cells by DNA-mediated transfection. Proc. Natl. Acad. Sci. USA. 79:1982;6777-6781.
29. Grable M., Hearing P. Cis and trans requirements of the selective packaging of adenovirus type 5 DNA. J. Virol. 66:1992;723-731.
30. Graham F. L., Smiley J., Russell W. C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:1977;59-72.
31. Hohlfeld R., Engel A. G. The immunobiology of muscle. Immunol. Today. 15:1994;269-274.
32. Hohlfeld R., Engel A. G. Induction of HLA-DR expression on human myoblast with interferon-gamma. Am. J. Pathol. 136:1990;503.
33. Huang S. E., Endo R. I., Nemerow G. R. Upregulation of integrins alpha-v-beta-3 and alpha-v-beta-5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J. Virol. 69:1995;2257-2263.
34. Ishii H., Kobayashi Y., Kuroki M., Kodama Y. Protection of mice from lethal infection with Aujeszky's disease virus by immunization with purified gVI. J. Gen. Virol. 69:1988;1411-1414.
35. Imler J.-L., Dupuit F., Chartier C., Accart N., Dieterle A., Schultz H., Puchelle E., Pavirani A. Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. Gene Ther. 3:1996;49-58.
36. Johnson R. M., Lancki D. W., Fitch F. W., Spear P. G. Herpes simplex virus glycoprotein D is recognized as antigen by CD4+ and CD8+ T lymphocytes from infected mice. J. Immunol. 148:1990;702-710.
37. Kaufman R. J. Identification of the components necessary for adenovirus translation control and their utilization in cDNA expression vectors. Proc. Natl. Acad. Sci. USA. 82:1985;689-693.
38. Li Z., Paulin D. Different factors interact with myoblast-specific and myotube-specific enhancer regions of the human desmin gene. J. Biol. Chem. 268:1993;10403-10415.
39. Li Z., Paulin D. High level desmin expression depends on a muscle-specific enhancer. J. Biol. Chem. 266:1991;6562-6570.
40. Manickan E., Rouse R. J. D., Yu Z., Wire W. S., Rouse B. T. Genetic immunization against herpes simplex virus: Protection is mediated by CD4+ T lymphocytes. J. Immunol. 155:1995;259-265.
41. Marchioli C. C., Yancey R. J., Petrovskis E. A., Timmins J. G., Post L. E. Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and chinese hamster ovary cells. J. Virol. 61:1987;3977-3982.
42. Marchioli C., Yancey R. J., Timmins J. G., Post L. E., Young B. R., Povendo D. A. Protection of mice and swine from pseudorabies virus-induced mortality by administration of pseudorabies virus-specific mouse monoclonal antibodies. Am. J. Vet. Res. 49:1988;860-864.
43. Metcalf J. F., Chatterjee S., Koga J., Whitley R. J. Protection against herpetic ocular disease by immunotherapy with monoclonal antibody to herpes simplex virus glycoproteins. Intervirology. 29:1988;39-49.
44. Mettenleiter T. C. Immunobiology of pseudorabies (Aujeszky's disease). Vet. Immunol. Immunopathol. 54:1996;221-229.
45. Mishkin E. M., Fahey J. R., Kino Y., Klein R. J., Abramovitz A. S., Mento S. J. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models. Vaccine. 9:1991;147-153.
46. Mittal S. K., Papp Z., Tikoo S. K., Baca-Estrada M. E., Yoo D., Benko M., Babiuk L. A. Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD. Virology. 222:1996;299-309.
47. Okuda K., Bukawa H., Hamajima K., Kawamoto S., Sekigava K.-I., Yamada Y., Tanaka S.-I., Ishii N., Aoki I., Nakamura M., Yamamoto H., Cullen B. R., Fukushima J. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res. Hum. Retroviruses. 11:1995;933-943.
48. Overell R. W., Weisser K. E., Hess B. W., Ziegler S. F., Pleiman C. M., Maliszewski C., Grabstein K. H. Efficient gene transfer and expression in primary B lymphocytes. J. Immunol. Methods. 141:1991;53-62.
49. Prevec L., Schneider M., Rosenthal K. L., Belbeck L. W., Derbyshire J. B., Graham F. L. Use of human adenovirus-based vectors for antigen expression in animals. J. Gen. Virol. 70:1989;429-434.
50. Quantin B., Perricaudet L. D., Tajbakhsh S., Mandel J.-L. Adenovirus as an expression vector in muscle cells in vivo. Proc. Natl. Acad. Sci. USA. 89:1992;2581-2584.
51. Ragot T., Finerty S., Watkins P. E., Perricaudet M., Morgan A. J. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J. Gen. Virol. 74:1993;501-507.
52. Randrianarison-Jewtoukoff V., Perricaudet M. Recombinant adenoviruses as vaccines. Biologicals. 23:1995;145-157.
53. Riviere M., Tartaglia J., Perkus M. E., Norton E. K., Molnar, Bongermino C., Lacoste F., Duret C., Desmettre P., Paoletti E. Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants. J. Virol. 66:1992;3424-3434.
54. Schirmbeck R., Bohm W., Ando K., Chisari F. V., Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J. Virol. 69:1995;5929-5934.
55. Schwartz B., Vicart P., Delouis C., Paulin D. Mammalian cell lines can be efficiently established in vitro upon expression of the SV40 large T antigen driven by a promoter sequence derived from the human vimentin gene. Biol. Cell. 73:1991;7-14.
56. Ulmer J. B., Donnelly J. J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., DeWitt C. M., Friedman A., Hawe L. A., Leander K. R., Martinez D., Perry H. C., Shiver J. W., Montgomery D. L., Liu M. A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
57. Wang B., Ugen K. E., Srikantan V., Agadjanyan M. G., Dang K., Refaeli Y., Sato A. I., Boyer J., Williams W. V., Weiner D. B. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 90:1993;4156-4160.
58. Wathen M. W., Wathen L. M. K. Isolation, characterization, and physical mapping of a pseudorabies virus mutant containing antigenically altered gp50. J. Virol. 51:1984;57-62.
59. Wolff J. A., Malone R. W., Williams P., Chong W., Ascadi G., Jani A., Felgner P. L. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
60. Xiang Z. Q., Spitalnik S. L., Cheng J., Erickson J., Wojczyk B., Ertl H. C. J. Immune responses to nucleic acid vaccines to rabies virus. Virology. 209:1995;569-579.
61. Xu Z. Z., Krougliak V., Prevec L., Graham F. L., Both G. W. Investigation of promoter function in human and animal cells infected with human recombinant adenoviruses expressing rotavirus antigen VP7sc. J. Gen. Virol. 76:1995;1971-1980.
62. Yokoyama M., Zhang J., Whitton J. L. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J. Virol. 69:1995;2684-2688.